NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
Want to see NRXP full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.98Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial forward progress across multiple fronts: near-term regulatory and manufacturing milestones for KETAFREE, an NRX-100 NDA supported by >65,000-patient RWE, FDA clearance to proceed with a sizable NRX-101 TMS augmentation trial (MIND1), expansion of HOPE clinics, and acquisition of Geneuro assets to broaden the pipeline. Financially, reported net loss improved materially (a 74% reduction year-over-year) and the company raised ~$7.0M post-quarter, while becoming debt-free. Counterbalancing these positives are near-term operational cash sensitivity, increased operating losses driven by higher R&D and G&A spend, ongoing regulatory timing risk, the need to build commercial channels (particularly to displace compounding pharmacy supply to clinics), and dependence on anticipated nondilutive funding for certain programs. Overall, the balance of concrete regulatory/operational advances and capital actions alongside manageable but material execution and timing risks supports a constructive outlook.Company Guidance
KETAFREE Regulatory and Manufacturing Progress
FDA provided a preliminary determination of bioequivalence for KETAFREE with only minor labeling and administrative quality items remaining; FDA leadership expressed support for addressing remaining items within the current review cycle targeting summer 2026. Manufacturing site reclassified to VAI status and the company transmitted its first commercial manufacturing order at a 1 million unit per batch scale. The blow-fill-seal (BFS) process offers >10x throughput vs traditional vial methods and is claimed capable of producing ~1 million units per week. KETAFREE will be the first U.S.-manufactured preservative-free ketamine and is free of benzethonium chloride; launch inventory target is at least 1 million units in warehouse.
NRX-100 NDA Supported by Substantial RWE
Type C meeting with FDA confirmed willingness to review existing clinical data together with real-world evidence (RWE). NDA expected to be filed in Q2 2026 supported by clinical data on >1,000 patients and RWE on >65,000 unique patients via partnership with Osmind. FDA guided pursuit of a broader depression indication including patients with suicidality. Company has Fast Track status and has applied for a Commission's National Priority voucher.
NRX-101 and MIND1 Trial Advancement
Initiated an NDA filing for NRX-101 (Module 3 manufacturing files submitted) and requested rolling review under Breakthrough Therapy designation. On May 7 FDA cleared the MIND1 Phase IIb/III trial (NRX-101 vs placebo as adjunct to robotic-assisted TMS) designed to enroll 400 participants across academic, HOPE clinics and U.S. military treatment facilities; nondilutive federal funding is anticipated. Company validated a proprietary extended-release D-cycloserine formulation to support TMS augmentation and formed NRx Defense Systems to run the program.
HOPE Therapeutics Network Expansion and Technology Integration
Operated five HOPE Therapeutics clinics during the quarter and expects 8+ locations by end of Q2. Added Professor Josh Brown as Chief Medical Innovation Officer and partnered with EMOBOT Health to deploy an AI-driven depression monitoring app; plan to integrate EMOBOT across network. Continued partnership with neurocare AG and an installed base of >400 Apollo TMS machines to expand service capacity. HOPE clinics are generating revenue and contributing to the commercial footprint.
Geneuro Asset Acquisition Broadens Pipeline
Acquired Geneuro SA assets (via Swiss court-supervised sale) adding patents, cell lines, antibodies, regulatory files and data from pre-completed human trials targeting HERVs implicated in schizophrenia, MS, ALS, autism and optic neuritis. Dr. Herve Perron joined as Chief Scientist and Professor Marion Leboyer will lead the anti-HERV-W program. Company expects to support Geneuro through nondilutive investment channels.
Financial Improvement and Post-Quarter Capital Raise
Reported net loss of ~$1.4M ($0.04/share) for Q1 2026 vs ~$5.5M ($0.34/share) in Q1 2025, representing a 74% year-over-year reduction in reported net loss. Company is now debt-free after having been $8.7M in debt a year ago. Cash and equivalents were ~$6.7M at March 31, 2026 and the company subsequently generated approximately $7.0M in gross proceeds from its at-the-market facility after quarter-end.
NRXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NRXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 18, 2026 | $3.28 | $3.12 | -5.03% |
Mar 24, 2026 | $1.77 | $2.13 | +20.34% |
Nov 17, 2025 | $2.49 | $2.11 | -15.26% |
Aug 18, 2025 | $2.76 | $2.50 | -9.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NRX Pharmaceuticals (NRXP) report earnings?
NRX Pharmaceuticals (NRXP) is schdueled to report earning on Aug 17, 2026, Before Open (Confirmed).
What is NRX Pharmaceuticals (NRXP) earnings time?
NRX Pharmaceuticals (NRXP) earnings time is at Aug 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXP EPS forecast?
NRXP EPS forecast for the fiscal quarter 2026 (Q2) is -0.07.